CytoSorbents Announces NASDAQ Inducement Grants to Drive Future Growth

PRINCETON, N.J., August 16, 2024 — CytoSorbents Corporation CTSO, a company at the forefront of developing life-saving treatments in critical care and cardiac surgery through its innovative blood purification technologies, has publicly disclosed the recent inducement grants offered under Nasdaq Listing Rule 5635(c)(4). These specific stock grants are intended as an inducement for newly hired employees, acting as a catalyst for future growth and development within the company.

CytoSorbents Expands with Inducement Grants

The inducement grants have been announced as a strategic initiative to attract and retain top talent that can further CytoSorbents' mission to address dire medical conditions in the intensive care unit (ICU). The company's proprietary technology utilizes advanced polymer adsorption techniques to detoxify blood, aiding patients suffering from life-threatening illnesses. With this move, CTSO is poised to enhance its workforce and bolster its position in the market.

Advancing Critical Care Through Innovation

CTSO's continued focus on innovation in the treatment of critical health conditions lies at the heart of its operations. The company, based in Monmouth Junction, New Jersey, leverages its proprietary adsorbent polymer technology to develop medical devices that can alleviate the burdens of illness. Through these inducement grants, CTSO reinforces its dedication to advancing medical treatments and underpins its commitment to leadership in critical care immunotherapy.

A Step Toward Enhanced Shareholder Value

The grants are not just a tool for human resource development, but also an investment in CytoSorbents' future success. Offering such incentives aligns with the interests of shareholders as they can potentially lead to groundbreaking developments, drive performance, and ultimately contribute to increased shareholder value over the long term. It is a strategic measure that paves the way for CTSO to fulfill its objective of superior patient care through medical innovation and to sustain its growth trajectory in the competitive healthcare marketplace.

CytoSorbents, NASDAQ, InducementGrants